On March 6, 2018 – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, reported that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 30th Annual ROTH Conference at 1:00 pm PT (4:00 pm ET) on Tuesday, March 13, 2018, at the Ritz Carlton in Dana Point, CA (Press release, Tracon Pharmaceuticals, MAR 6, 2018, View Source [SID1234524976]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentation" section within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

On March 6, 2018 Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference, March 12, 2018, at 11:20 am ET (Press release, Five Prime Therapeutics, MAR 6, 2018, http://investor.fiveprime.com/news-releases/news-release-details/five-prime-therapeutics-present-cowen-and-company-38th-annual [SID1234524645]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On March 6, 2018 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, areported that it will be presenting at the 30th Annual ROTH Conference, being held on March 11-14, 2018 in Dana Point, California and participate in a NASH panel discussion titled "News is Great, Novel is Better" (Press release, Can-Fite BioPharma, MAR 6, 2018, View Source [SID1234524641]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel discussions on the latest topics and developments in NASH/PBC drug development span two days at the Roth Conference and are slated to feature 20 public and private companies in the field of liver diseases, 8 renowned Key Opinion Leaders, 3 NASH/PBC patients, and The American Liver Foundation.

In addition, Dr. Fishman will deliver the Company’s corporate presentation and provide updates on its lead drug candidate, Piclidenoson (CF101), currently in a Phase III trial for rheumatoid arthritis and is expected to enter a Phase III trial for psoriasis during 2018. The Company’s liver drug Namodenoson (CF102) is in a Phase II trial for patients with advanced liver cancer and is in a Phase II trial for the treatment of NAFLD/NASH.

The company recently provided an update on the progress of its ongoing Phase II NASH study and anticipates the completion of patient enrollment toward the end of 2018 and data release in the first half of 2019.

There is currently no U.S. FDA approved drug for the treatment of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.

on March 6, 2018 argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that its Chief Executive Officer, Tim Van Hauwermeiren, will present on Tuesday, March 13th at 10:40 a.m. ET at the Cowen and Company 38th annual Health Care Conference in Boston (Press release, , JUN 6, 2018, View Source [SID1234524625]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the argenx’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following the presentation.

On March 6, 2018 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that the company will make a presentation at the following upcoming event (Press release, , JUN 6, 2018, View Source [SID1234524624]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Barclays Global Healthcare Conference – Miami, March 13, at 1:35 p.m. EDT

A webcast of the event may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.